A clinical trial of VTA 100 for the treatment of Limb-girdle-muscular-dystrophies (LGMD)
Latest Information Update: 18 Oct 2022
At a glance
- Drugs VTA-100 (Primary)
- Indications Limb girdle muscular dystrophies
- Focus Adverse reactions; First in man
- 13 Oct 2022 According to a Vita Therapeutics media release, SOLVE FSHD invests US$10 Million in Vita Therapeutics, proceeds from the financing will be used to advance this trial.
- 22 Mar 2022 According to a Vita Therapeutics media release, the company expect to file investigational drug applications with the US Food and Drug Administration in 2023.
- 30 Jun 2021 New trial record